People with end stage ALS lose the ability to breathe, have limited mobility as muscles become paralyzed, and may no longer be able to speak. Amyotrophic lateral sclerosis (ALS) affects certain nerve ...
Clinical Trials Arena on MSN
Spinogenix’s ALS hopeful to advance to registrational trial
"Spinogenix’s ALS hopeful to advance to registrational trial" was originally created and published by Clinical Trials Arena, ...
LOS ANGELES, March 31, 2025 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to targeting cancer and autoimmune diseases through ...
SPG302 was well tolerated in a trial, with preliminary data supporting the idea the therapy might slow ALS progression.
Spinogenix received FDA authorization earlier this year for an Expanded Access Program, providing access to 200 ALS individuals ineligible for clinical trials in the United States. SPG302 has also ...
The early-stage pipeline for amyotrophic lateral sclerosis drugs exploded last year. After ALS R&D notched 28 new trial starts in 2023, the rate more than doubled to 60 in 2024, Citeline recently ...
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disorder that robs individuals of the ability to control muscle movement. Although ALS is clearly a neurologic disorder involving ...
The 36-year-old content creator posted a "dying diary" to describe the feeling of her progressing paralysis Zoey Lyttle is a Society & Culture Writer-Reporter at PEOPLE. She covers influencers and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback